Get informed when a big investor buys or sells
+ FollowLoading insider trades…
Loading congress trades…
| Market cap | $167.66 Million |
|---|---|
| Enterprise Value | $159.90 Million |
| Earnings per Share | $0.16 |
| Beta | 5.67 |
| Outstanding Shares | 43,891,200 |
| P/E Ratio | 19.75 |
|---|---|
| PEG | -6 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 11.18 |
| Enterprise Value to EBIT | 25.17 |
| Enterprise Value to Net Income | 22 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
No data
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Holdings and activity of institutional investors.
| Ownership % | 0.24%▲ 0.08% |
|---|---|
| Total Invested | $676,193▼ 31.36% |
| Investors Holding | 14▲ 2.00% |
Anbio Biotechnology, established in 2021 and based in Frankfurt am Main, Germany, operates as a global supplier of in vitro diagnostics (IVD) products. The company's international footprint covers regions such as the European Union, Asia...